Posted by Michael Wonder on 18 Mar 2022
Update to the statutory scheme to control the costs of branded health service medicines
15 March 2022 - The UK Government is seeking views on its proposal to increase the rate of payments made by pharmaceutical companies who are members of the statutory scheme payment in 2022 and 2023.
This is to ensure it can continue to control growth in medicines sales under the statutory scheme at a rate of 1.1% and continue to maintain broad commercial equivalence with the voluntary scheme for Branded Medicines Pricing and Access 2019.
